Connect with us

Cyber Crime

Pharma Giant Alkem Laboratories Faces Security Breach, Rs 52 Crores at Stake

Published

on

Pharma Giant Alkem Laboratories Faces Security Breach, Rs 52 Crores at Stake

MUMBAI:  Pharmaceutical giant Alkem Laboratories confirmed Friday that a cybersecurity incident led to a fraudulent transfer of Rs 52 crore from one of its subsidiaries. While the company maintained the impact was minimal and confined to a specific incident, the disclosure raises concerns about vulnerabilities in India’s pharmaceutical sector to cyberattacks.

Compromised Emails, But Limited Impact?

Without revealing the exact nature of the security breach, Alkem stated that fraudulent actors compromised the business email IDs of some employees at its subsidiary. Though the amount stolen wouldn’t trigger mandatory reporting thresholds as per company policy, the Board of Directors chose transparency, disclosing the incident to the stock exchanges.

ALSO READ: Registrations are now OPEN for the “FutureCrime Summit 2024”. Register Now!

CLICK HERE TO REGISTER

“The report concluded that the impact didn’t extend beyond the mentioned amount,” said the company filing. “However, in the interest of transparency and good governance, the Board chose to report the incident.”

Independent Probe and Reassurances

Alkem appointed an independent external agency to investigate the incident and filed complaints with relevant authorities. They emphasized that the fraud wasn’t linked to any internal misconduct by promoters, directors, or employees. Additionally, the company highlighted its recent partnership with Check Point Software Technologies, a cybersecurity solutions provider, to bolster its defenses against cyberattacks.

ALSO READ: FutureCrime Summit 2024: Nominations Open for Top Honors in Cybersecurity

A Wake-Up Call for Pharmaceutical Cybersecurity

While Alkem emphasizes the limited impact of the incident, the episode shines a light on the cybersecurity landscape of India’s pharmaceutical sector. These companies hold invaluable intellectual property and sensitive patient data, making them prime targets for cybercriminals. Alkem’s case serves as a cautionary tale, highlighting the need for robust cybersecurity measures and increased vigilance within the industry.

ALSO READ: FutureCrime Summit 2024: Nominations Open for Top Honors in Cybersecurity

The incident raises several questions: What vulnerabilities allowed the attack? How widespread is the threat across the pharmaceutical sector? What steps are being taken to ensure better protection of sensitive data? With Alkem choosing transparency, perhaps this incident can catalyze broader conversations and proactive measures to safeguard India’s pharmaceutical sector from the growing menace of cybercrime.

Follow The420.in on

 Telegram | Facebook | Twitter | LinkedIn | Instagram | YouTube

Continue Reading